Cancer Immunotherapy

The immune system normally patrols the body for abnormal cells, but many cancers learn to switch off this defence by pressing molecular brakes, known as checkpoints, on immune cells. Checkpoint inhibitors are antibodies that block these brakes, most commonly the PD-1, PD-L1 and CTLA-4 pathways, so that the immune cells can once again see and attack the tumour. This is a form of biological therapy, meaning it is based on molecules that act on the body's own systems rather than on chemicals that directly poison dividing cells. Because the treatment works indirectly, through the immune response, the pattern of side effects is different from chemotherapy: instead of hair loss and a drop in marrow cells, the main concern is an over-active immune system that can inflame healthy tissues, which the team watches for and treats early. Related cell-based approaches, such as cell therapies, are handled separately, and immunotherapy here refers to the drug treatments given by infusion.

Immunotherapy is considered for a growing list of solid tumours and some blood cancers, including lung cancer, melanoma, kidney cancer, bladder cancer, head and neck cancer and certain lymphomas. Whether it is suitable depends heavily on features of the individual tumour, which is why biomarker testing is central: tests for PD-L1 levels, microsatellite instability (MSI) and other markers help predict who is more likely to benefit. It may be used at different stages, sometimes as a first treatment, sometimes after other treatments, and sometimes alongside chemotherapy or radiotherapy to improve the overall effect. It can also be given after surgery in selected cases to lower the chance of the cancer returning. The decision is made by a medical oncology team after reviewing the cancer type, stage, biomarker results, previous treatments and the person's general health, and it is always tailored to the individual rather than applied as a fixed rule.

Immunotherapy is usually given as an intravenous infusion, a drip into a vein, in a day-case unit without an overnight stay. Before each cycle there are blood tests and a clinical review to check that it is safe to proceed. A single infusion commonly takes around thirty to sixty minutes, after which most people go home the same day. Treatment is given in cycles, often every two to six weeks depending on the specific medicine and plan, and a course can continue for several months or longer while the response is monitored with scans and blood tests. Some regimens combine two immunotherapy drugs, or pair immunotherapy with chemotherapy given on the same visit. Because the schedule is spread over months, the team plans the cycles in advance so that treatment and daily life, including any travel, can be organised together.

A suitable candidate has a cancer type and biomarker profile that point to possible benefit, is well enough for regular outpatient treatment, and has had the plan reviewed by a medical oncology team. Preparation includes up-to-date imaging, blood tests, and biomarker testing on tumour tissue such as PD-L1 and MSI, which may require reviewing an existing biopsy or, occasionally, taking a fresh sample. Because immunotherapy acts on the immune system, the team asks carefully about autoimmune conditions and long-term steroid or immune-suppressing medicines, as these can affect suitability and monitoring. Existing medicines are reviewed and adjusted on medical advice. For international patients, the assessment can begin from home, with recent scans, pathology reports, biomarker results and a medical summary reviewed remotely so the team can advise on suitability before travel and explain how the cycles will be spaced.

Immunotherapy is generally given on an outpatient basis, so there is no surgical recovery, and most people continue their usual activities on the same day as an infusion. The main planning challenge is that treatment runs as a course over months rather than a single visit. For this reason, international patients often arrange the first cycles and assessment at the specialised centre and then continue later cycles or monitoring closer to home, following a shared plan agreed with the team. Air travel is normally fine, and the team will advise on timing around each cycle and on what symptoms to watch for after returning. Because immune-related side effects can appear days or weeks after an infusion, patients are given clear guidance on warning signs and how to reach medical help quickly wherever they are. International patient teams commonly arrange interpreters and coordinators so that this longer-term communication stays straightforward.

Immunotherapy is generally better tolerated than intensive chemotherapy, but it has its own pattern of side effects that the team monitors closely. Because it activates the immune system, it can sometimes cause immune-related reactions in which the body inflames its own tissues, affecting areas such as the skin, bowel, thyroid and other glands, liver or lungs. Most of these are mild and manageable, especially when reported early, but some can be serious and need prompt treatment, which is why regular reviews and blood tests are part of the plan. Common milder effects include tiredness, skin rash and joint aches. The benefit varies widely between individuals and cancer types: for some people immunotherapy can produce durable control of the disease, while for others the response is limited, and biomarker testing helps but cannot fully predict this. Results depend on the cancer type, its biology and the experience of the team, which is why it is best delivered where these treatments and their side effects are managed regularly.